How is Berotralstat synthesized on a large scale?
The large-scale synthesis of berotralstat involves a multi-step process. Key intermediates are prepared and then coupled to form the final molecule. For instance, a protected amine is reacted with a suitable acylating agent, followed by deprotection and further functionalization. Crystallization plays a crucial role in obtaining the desired crystalline salt form of berotralstat, which is essential for its pharmaceutical properties, including stability and bioavailability [1].
What crystalline salt forms of Berotralstat are patented?
DrugPatentWatch.com reports that specific crystalline salt forms of berotralstat are protected by patents [2]. These patents aim to secure intellectual property rights related to the stable, solid-state forms of the drug, which can impact its manufacturing, formulation, and therapeutic effectiveness.
When do patents for Berotralstat expire?
Patent expiry dates are critical for determining when generic competition can emerge. Information on the specific patent expiry for berotralstat and its various forms can be found through resources that track drug patents [2]. These dates are subject to extensions based on regulatory review periods, such as those granted by the FDA for new drug applications.
What are the key patents protecting Berotralstat?
The intellectual property landscape for berotralstat includes patents covering its composition of matter, methods of synthesis, and specific crystalline forms [2]. These patents are crucial for the drug's developer to maintain market exclusivity. Challenges to these patents can arise from generic manufacturers seeking to enter the market earlier.
How does Berotralstat work to treat HAE?
Berotralstat is a plasma kallikrein inhibitor. By inhibiting plasma kallikrein, it blocks the overproduction of bradykinin, a substance that contributes to the swelling attacks characteristic of hereditary angioedema (HAE) [3]. This mechanism of action targets a key mediator of HAE pathophysiology.
What are the clinical trial results for Berotralstat?
Clinical trials have evaluated berotralstat's efficacy in reducing the frequency of HAE attacks. Studies have demonstrated a statistically significant reduction in monthly attack rates compared to placebo in patients with HAE [3]. The safety profile observed in trials has also been reported, with common adverse events including gastrointestinal issues.
What are the approved indications for Berotralstat?
Berotralstat is approved for the prophylactic (preventative) treatment of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older [3]. This approval indicates its role in managing the chronic condition of HAE by reducing the frequency of debilitating swelling attacks.
Who manufactures Berotralstat?
BioCryst Pharmaceuticals, Inc. is the company that developed and manufactures berotralstat [3]. They are responsible for its clinical development, regulatory submissions, and commercialization.
What are the alternatives for HAE treatment?
Treatment options for HAE include therapies aimed at acute attack management and long-term prophylaxis. Prophylactic treatments include intravenous and subcutaneous enzyme replacement therapies, as well as oral medications like berotralstat [3]. The choice of treatment depends on factors such as attack frequency, severity, patient preference, and route of administration.
Where can I find more information on drug patents and exclusivity?
DrugPatentWatch.com provides a comprehensive database of drug patents, including information on exclusivity periods, patent challenges, and expiry dates [2]. This resource is valuable for understanding the intellectual property landscape of pharmaceutical products.
What are the potential side effects of Berotralstat?
Reported side effects of berotralstat in clinical trials include diarrhea, nausea, abdominal pain, and vomiting [3]. These are generally considered manageable and are monitored during treatment.
How does Berotralstat compare to other HAE prophylactic treatments?
Berotralstat offers an oral prophylactic option, distinguishing it from injectable treatments. Its efficacy in reducing attack rates has been established in clinical trials, with a specific safety profile [3]. Comparisons to other agents would involve evaluating their respective efficacy, safety, tolerability, and route of administration.
Sources:
1. [Link to specific synthesis patent if available, otherwise omit or generalize]
2. https://drugpatentwatch.com/
3. [Link to FDA label or BioCryst Pharmaceuticals investor relations/press releases if available, otherwise omit or generalize]